Avidity Biosciences Inc. (RNA) News

Avidity Biosciences Inc. (RNA): $12.95

0.65 (+5.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 388

in industry

Filter RNA News Items

RNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RNA News Highlights

  • RNA's 30 day story count now stands at 3.
  • Over the past 13 days, the trend for RNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest RNA News From Around the Web

Below are the latest news stories about Avidity Biosciences Inc that investors may wish to consider to help them evaluate RNA as an investment opportunity.

Avidity Biosciences Appoints Steve Hughes, M.D., as Chief Medical Officer

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.

Yahoo | February 23, 2022

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:

Yahoo | February 11, 2022

Avidity Biosciences (NASDAQ:RNA) investors are sitting on a loss of 25% if they invested a year ago

It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both...

Yahoo | February 10, 2022

Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

Yahoo | December 23, 2021

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down to $24.32

Avidity Biosciences, Inc. (NASDAQ:RNA)s share price gapped down before the market opened on Friday . The stock had previously closed at $24.32, but opened at $22.15. Avidity Biosciences shares last traded at $22.71, with a volume of 101 shares changing hands. RNA has been the topic of a number of research analyst reports. Evercore ISI []

Dakota Financial News | December 19, 2021

Avidity Biosciences (RNA) Buy Rating Reaffirmed at Wells Fargo & Company

Wells Fargo & Company restated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA) in a research note issued to investors on Friday morning, TipRanks reports. They currently have a $59.00 price objective on the biotechnology companys stock. A number of other equities analysts also recently commented on the stock. SVB Leerink boosted their target []

Transcript Daily | December 14, 2021

SVB Leerink Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $53.00

Avidity Biosciences (NASDAQ:RNA) had its price objective lifted by SVB Leerink from $36.00 to $53.00 in a report issued on Friday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other analysts have also recently issued reports about the company. Evercore ISI began coverage on Avidity Biosciences […]

Dakota Financial News | December 14, 2021

Avidity Biosciences (NASDAQ:RNA) Shares Up 6.6% After Analyst Upgrade

Avidity Biosciences, Inc. (NASDAQ:RNA)’s share price shot up 6.6% during mid-day trading on Monday after SVB Leerink raised their price target on the stock from $36.00 to $53.00. SVB Leerink currently has an outperform rating on the stock. Avidity Biosciences traded as high as $26.02 and last traded at $25.98. 1,505 shares were traded during […]

Dakota Financial News | December 14, 2021

Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $53.00

Avidity Biosciences (NASDAQ:RNA) had its target price increased by equities researchers at SVB Leerink from $36.00 to $53.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The firm presently has an outperform rating on the biotechnology companys stock. SVB Leerinks target price points to a potential upside of []

Transcript Daily | December 12, 2021

Wells Fargo & Company Reiterates Buy Rating for Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences (NASDAQ:RNA)s stock had its buy rating reiterated by equities researchers at Wells Fargo & Company in a report issued on Friday, TipRanks reports. They presently have a $59.00 price objective on the biotechnology companys stock. Wells Fargo & Companys target price suggests a potential upside of 142.10% from the companys previous close. Several []

Dakota Financial News | December 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4343 seconds.